Suven announces merger of Cohance Lifesciences
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
We are achieving the target of developed India by making our young children healthy today
The project aims at screening the general health condition of the students enrolled in classes 6th to 12th.
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The company will be managing orders and warehouse operations for Little's, Lacto-calamine, Tri-activ, I-feel, Ourdaily, and Sloan's through the Unicommerce platform
Subscribe To Our Newsletter & Stay Updated